Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.56 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.55 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 7/20 | 0.54 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.54 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | JUN | P05412 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MTTP | P55157 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284516 | 0.83 | P2RX1 (0.71) | P2RX1P2RX4P2RX7TMPRSS4P2RX3 | |
| SCHEMBL131701 | 0.80 | P2RX1 (0.71) | P2RX1P2RX4P2RX7TMPRSS4P2RX3 | |
| SCHEMBL28568150 | 0.77 | RUVBL1 (0.79) | RUVBL1SMN1; SMN2HTT | |
| SCHEMBL17973447 | 0.76 | P2RX1 (0.51) | RUVBL1RXFP1P2RX1P2RX4P2RX7 | |
| SCHEMBL34475343 | 0.76 | GPR27 (0.60) | AVPR2GPR27RXFP1ABCB1NR1H4 | |
| SCHEMBL3143282 | 0.75 | CTSD (0.64) | ABCB1NR1H4SMN1; SMN2HTT | |
| SCHEMBL133550 | 0.75 | P2RX1 (0.63) | RXFP1P2RX1P2RX4P2RX7TMPRSS4 | |
| SCHEMBL5491795 | 0.75 | RXFP1 (0.88) | RXFP1P2RX1 | |
| SCHEMBL11308149 | 0.74 | CHEK1 (0.59) | ABCB1NR1H4SMN1; SMN2 | |
| SCHEMBL16709939 | 0.74 | TMPRSS4 (0.68) | P2RX1P2RX4P2RX7TMPRSS4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060089395-A1 | Nf-kb activation inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-02-16 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | RUVBL1 3307/4885AVPR2 4762/4885GPR27 2741/4885 |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | RUVBL1 2751/4885AVPR2 1677/4885GPR27 1988/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | RUVBL1 4717/4885AVPR2 665/4885GPR27 1260/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | RUVBL1 4610/4885AVPR2 565/4885GPR27 330/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | RUVBL1 4312/4885AVPR2 1529/4885GPR27 2439/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | RUVBL1 4553/4885AVPR2 713/4885GPR27 427/4885 |
| US-20080234233-A1 | MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAPT, TFEB, MAOA | RUVBL1 4226/4885AVPR2 1741/4885GPR27 2481/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | RUVBL1 3668/4885AVPR2 2281/4885GPR27 1804/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | RUVBL1 4632/4885AVPR2 554/4885GPR27 389/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | RUVBL1 4601/4885AVPR2 590/4885GPR27 376/4885 |
| US-20060089395-A1 | Nf-kb activation inhibitors | NFKBIA, IKBKB, NFRKB | RUVBL1 1373/4885AVPR2 3197/4885GPR27 4018/4885 |
| US-20060035944-A1 | Remedies for neurodegenerative diseases | GLA, CHAT, MAPT | RUVBL1 4250/4885AVPR2 2675/4885GPR27 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.